Nichols & Pratt Advisers LLP MA Sells 734 Shares of Solventum Co. (NYSE:SOLV)

Nichols & Pratt Advisers LLP MA reduced its stake in Solventum Co. (NYSE:SOLV) by 12.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 5,281 shares of the company’s stock after selling 734 shares during the period. Nichols & Pratt Advisers LLP MA’s holdings in Solventum were worth $349,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in the stock. Modus Advisors LLC bought a new stake in Solventum during the fourth quarter valued at $25,000. Stonebridge Financial Group LLC bought a new stake in Solventum during the fourth quarter valued at $26,000. True Wealth Design LLC lifted its stake in Solventum by 23,550.0% during the third quarter. True Wealth Design LLC now owns 473 shares of the company’s stock worth $33,000 after purchasing an additional 471 shares during the last quarter. Crews Bank & Trust bought a new stake in Solventum during the fourth quarter worth about $32,000. Finally, Prospera Private Wealth LLC bought a new stake in Solventum during the third quarter worth about $35,000.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on SOLV shares. Piper Sandler lifted their price target on Solventum from $75.00 to $84.00 and gave the stock a “neutral” rating in a research note on Friday. Bank of America lifted their price objective on Solventum from $80.00 to $85.00 and gave the stock a “neutral” rating in a report on Wednesday. Wells Fargo & Company lifted their price objective on Solventum from $73.00 to $75.00 and gave the stock an “equal weight” rating in a report on Friday. Mizuho began coverage on Solventum in a report on Wednesday, December 4th. They issued a “neutral” rating and a $70.00 price objective on the stock. Finally, Morgan Stanley lifted their price objective on Solventum from $60.00 to $73.00 and gave the stock an “equal weight” rating in a report on Monday, November 11th. One analyst has rated the stock with a sell rating, nine have given a hold rating and one has given a buy rating to the stock. Based on data from MarketBeat.com, Solventum currently has a consensus rating of “Hold” and an average target price of $74.71.

Solventum Stock Down 4.7 %

Shares of NYSE:SOLV opened at $79.56 on Friday. Solventum Co. has a 1 year low of $47.16 and a 1 year high of $96.05. The company has a market cap of $13.74 billion and a PE ratio of 28.93. The company has a debt-to-equity ratio of 2.45, a current ratio of 1.15 and a quick ratio of 0.83. The stock’s 50-day moving average is $72.51 and its 200 day moving average is $69.88.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.